<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02326311</url>
  </required_header>
  <id_info>
    <org_study_id>AOBSTMO-OPTKIMA-2014</org_study_id>
    <nct_id>NCT02326311</nct_id>
  </id_info>
  <brief_title>Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients ≥60 Years in Deep Molecular Response</brief_title>
  <official_title>Phase-III Randomized Study to Optimize TKIs Multiple Approaches - (OPTkIMA) - and Quality of Life (QoL) in Elderly Patients (≥60 Years) With Ph+ Chronic Myeloid Leukemia (CML) and MR3.0 / MR4.0 Stable Molecular Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliera Spedali Civili di Brescia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliera Spedali Civili di Brescia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this phase III clinical randomized study, &quot;fixed&quot; intermittent administration (one month
      ON/one month OFF) of TKIs (control arm), will be compared with &quot;progressive&quot; intermittent
      administration (one month ON/one month OFF for the 1st year; one month ON/two months OFF for
      the 2nd year; one month ON/three months OFF for the 3rd year) (experimental arm). Imatinib
      (Glivec), or Nilotinib (Tasigna), or Dasatinib (Sprycel) will be given intermittently at the
      same daily dose that was given daily at the time of the enrollment . Chronic phase Ph+ CML
      patients in stable major molecular response (MR3.0 or MR4.0) after ≥2 years of standard
      treatment with IM, NIL, or DAS will be randomized 1:1 to receive &quot;fixed&quot; INTERIM or
      &quot;progressive&quot; INTERIM. Randomization will be stratified by type of TKI (IM, NIL, or DAS,) and
      by depth of molecular response (MR3.0or MR4.0). The study is aimed to evaluate if a
      progressive increase of intermittent treatment discontinuation until 3 months is able to
      improve QoL outcomes with respect to &quot;fixed&quot; intermittent administration of TKIs (control
      arm) and to maintain MR3.0 / MR4.0 molecular response. Patients' self reported EORTC QLQ-C30
      outcome measure will be assessed throughout the three years follow up period. The QoL results
      in this trial will be presented in accordance with high methodological quality criteria for
      documenting patient-reported outcomes (PRO) data in RCTs, including the CONSORT PRO
      recommendations. Furthermore, the study could give additional clinical and biological
      information to optimize TKIs therapy in elderly.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in quality of Life</measure>
    <time_frame>Baseline (T0), and then at 3 (T1), 6 (T2), 12 (T3), 18 (T4), 24 (T5), 30 (T6), and 36 (T7) months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">502</enrollment>
  <condition>Leukemia, Chronic Myeloid</condition>
  <arm_group>
    <arm_group_label>Fixed INTERIM TKI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention: &quot;fixed&quot; intermittent administration (one month ON/one month OFF) of TKIs (imatinib, nilotinib, dasatinib)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Progressive INTERIM TKI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: &quot;progressive&quot; intermittent administration (one month ON/one month OFF for the 1st year; one month ON/two months OFF for the 2nd year; one month ON/three months OFF for the 3rd year) (imatinib, nilotinib, dasatinib)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>imatinib</intervention_name>
    <description>Tyrosin kinase inhibitor</description>
    <arm_group_label>Fixed INTERIM TKI</arm_group_label>
    <arm_group_label>Progressive INTERIM TKI</arm_group_label>
    <other_name>Glivec</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nilotinib</intervention_name>
    <description>Tyrosin kinase inhibitor</description>
    <arm_group_label>Fixed INTERIM TKI</arm_group_label>
    <arm_group_label>Progressive INTERIM TKI</arm_group_label>
    <other_name>Tasigna</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dasatinib</intervention_name>
    <description>Tyrosin kinase inhibitor</description>
    <arm_group_label>Fixed INTERIM TKI</arm_group_label>
    <arm_group_label>Progressive INTERIM TKI</arm_group_label>
    <other_name>Sprycell</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with a confirmed diagnosis of Ph+ CML in CP

          2. Age ≥ 60 years old

          3. Stable MR3.0/ MR4.0 after at least 2 years of treatment with standard (daily
             administration) IM, NIL, or DAS therapy; the stability of molecular response will be
             documented by at least 3 consecutive molecular analyses over the last 12 months.

          4. Having completed the QoL baseline evaluation (i.e., before randomization)

          5. Written informed consent prior to any study procedures

        Exclusion Criteria:

          1. Patients with Ph+ CML in accelerated/blastic phase (AP/BP), or in late CP previously
             treated (i.e. IFNalpha+/- low dose Ara-C, Hydroxurea, allogeneic stem cell
             transplantation, etc)

          2. Age &lt; 60 years old

          3. Less than 2 years of treatment with standard (continuous administration) IM, NIL or
             DAS therapy

        3. Absence of stable MR3.0/MR4.0 as documented by at least 3 consecutive molecular analyses
        over the last 12 months 4. No written informed consent prior to any study procedures. 5.
        Having any kind of psychiatric disorder or major cognitive dysfunction hampering a QoL
        evaluation (as judged by the physician).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Domenico Russo, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chair of Hematology, BMT Unit</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Domenico Russo, Professor</last_name>
    <phone>+390303996810</phone>
    <email>domenico.russo@unibs.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michele Malagola, MD</last_name>
    <phone>+390303996810</phone>
    <email>michelemalagola@yahoo.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Policlinico Universitario di Milano</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandra Iurlo, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 17, 2014</study_first_submitted>
  <study_first_submitted_qc>December 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 29, 2014</study_first_posted>
  <last_update_submitted>May 8, 2018</last_update_submitted>
  <last_update_submitted_qc>May 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliera Spedali Civili di Brescia</investigator_affiliation>
    <investigator_full_name>Prof Domenico Russo</investigator_full_name>
    <investigator_title>Full Professor of Hematology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
    <mesh_term>Dasatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

